Progesterone vs. Progestins: The Neurosteroid Gap

The biological mechanism of progesterone is far more complex than simple endometrial protection. While conventional medicine uses synthetic progestins like medroxyprogesterone acetate (MPA) primarily to prevent uterine hyperplasia during oestrogen replacement, it ignores the systemic necessity of bioidentical progesterone. Bioidentical progesterone is a precursor to allopregnanolone, a neurosteroid that crosses the blood-brain barrier and acts as a potent positive allosteric modulator of GABA-A receptors. This mechanism is responsible for the calming, sedative, and anti-anxiety effects of natural progesterone.

Synthetic progestins, due to their altered molecular structure, do not convert to allopregnanolone and can actually antagonise the beneficial effects of oestrogen on the cardiovascular system and the brain. Conventional medicine misses the neuro-protective and mood-stabilising requirements of the perimenopausal woman, often prescribing antidepressants when the actual deficiency is a lack of GABA-modulating neurosteroids. Research evidence, including the PEPI trial, demonstrates that micronised progesterone has a neutral effect on HDL cholesterol, whereas synthetic progestins lower it, increasing cardiovascular risk. Furthermore, environmental factors such as chronic alcohol consumption can deplete progesterone levels by increasing the clearance of the hormone through the liver.

Practical takeaways for the health-educated individual include insisting on micronised, bioidentical progesterone (such as Utrogestan in the UK) rather than synthetic progestins, and monitoring GABA-related symptoms like insomnia and social anxiety as primary indicators of progesterone status. It is also vital to consider the timing of administration, as oral micronised progesterone undergoes first-pass metabolism in the liver to produce the highest levels of sleep-inducing metabolites.